About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
  • Inducible T-Cell Costimulator (ICOS)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    T-cell activity is controlled by the interaction of a diverse network of ligands and receptors.1,2 The inducible T-cell costimulator (ICOS), a CD28 family member and important regulator of the adaptive immune response, is found on the surface of certain T cells, and its expression is upregulated upon stimulation by binding to the T-cell receptor (TCR).1-3 ICOS stimulation results in a costimulatory signal that may ultimately enhance T-cell function, including activity against tumor cells.4 ICOS is also present on a set of T regulatory cells.5 Targeting ICOS in cancer may potentially have a dual effect of modifying T-cell activity and depleting intratumoral T regulatory cells with high ICOS expression.5

    View Related Molecules

    References

    1. Simpson TR, et al. Curr Opin Immunol. 2010;22:326-332. PMID: 20116985
    2. Sharpe AH. Immunol Rev. 2009;229:5-11. PMID: 19426211
    3. McAdam AJ, et al. J Immunol. 2000;165:5035-5040. PMID: 11046032
    4. Fan X, et al. J Exp Med. 2014;211:715-725. PMID: 24687957
    5. Michaelson JS, et al. Cancer Res. 2016;76(suppl)[abstract 573].